Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...

Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD outside of Canada and the US) ...

BMS’ share price dived last year after Opdivo (nivolumab) failed in a clinical trial in this indication, and MSD’s rival has been approved in this use in the US and EU. Keytruda got EU ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Results have been announced from a Phase III trial of Merck & Co’s (NYSE: MRK) anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima (lenvatinib), Eisai’s (TYO: 4523) orally available multiple ...

The com­bi­na­tion of Mer­ck’s Keytru­da and Ei­sai’s Lenvi­ma failed to pro­long pa­tients’ lives ver­sus the com­para­tor in an­oth­er can­cer study, but the com­pa­nies ...

MSD and Eisai have announced mixed results from a Phase III trial of a Keytruda (pembrolizumab) combination as a first-line treatment for patients with metastatic human epidermal growth factor ...

Merck (NYSE:MRK) and Esai (OTCPK:ESALF) (OTCPK:ESAIY) announced Friday a mixed outcome in their Phase 3 LEAP-015 trial, which was designed to evaluate MRK’s anti-PD-1 therapy Keytruda and the Ja ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. The Keytruda-Lenvima regimen ...

Correction: This script has been updated with an added point MSD offered for context. ST. LOUIS – More than $10 million a minute—that’s the rate at which watchdog Tom Sullivan says the ...

There remains uncertainty about how much longer Keytruda can help patients live, as the data is still not mature. MSD says the drug could give second line patients as much as 11 months ...